漱玉平民(301017) - 301017漱玉平民投资者关系管理信息20250516

Financial Performance - In 2024, the company achieved a total revenue of 9.57 billion CNY, representing a year-on-year growth of 4.13% [2] - The net profit attributable to shareholders was -189 million CNY, a significant decline of 241.90% compared to the previous year [2] - In Q1 2025, the company reported a revenue of 2.379 billion CNY, a decrease of 2.48% year-on-year, with a net profit of 25.6239 million CNY, marking a growth of 143.85% compared to the same period last year [3] Shareholder Information - As of April 30, 2025, the total number of shareholders is 13,133 [4] Growth Strategies - Future profit growth will focus on: - Expansion of store networks through self-built, mergers, franchises, and alliances [4] - Digital transformation and new retail strategies to enhance operational efficiency and online penetration [4] - Development of proprietary brands and diversification of product lines, including health products targeting younger demographics [4] - Optimization of logistics and supply chain systems to support franchise expansion and improve procurement cost structure [4] Industry Outlook - The pharmaceutical retail industry is expected to maintain steady growth due to structural adjustments and strategic opportunities driven by factors such as an aging population and increased health awareness [5] Acquisition Status - The company has terminated the acquisition of Tian Shili, as approved by the board on December 28, 2023 [6]